Redhill snatches defeat from the jaws of victory in Crohn's
Redhill Biopharma has claimed success with its novel Crohn's disease therapy, but there is more to this "victory" than meets the eye.
Upcoming events – Crowded markets ahead for TG and Redhill
TG and Redhill are expecting phase III data soon, but both have a fight ahead to make their mark even if their projects succeed.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.